<prompt> Please answer with one of the option in the bracket. Write reasoning in between . Write answer in between .Q:A 3-year-old boy is diagnosed with an alpha-gal allergy, also known as mammalian meat allergy MMA. This condition is mediated by a reaction to the carbohydrate, galactose-alpha-1,3-galactose. An experimental treatment has been developed to halt the N-linked oligosaccharide addition that occurs in the synthesis of this compound. Which of the following cellular structures is most likely targeted by this experimental drug?? A: Golgi apparatus, B: Rough endoplasmic reticulum, C: Sodium-potassium pump, D: Proteasome, E: Tumor suppressor p53,  <response>: This is a question about the cellular biology behind alpha-gal allergy mammalian meat allergy. The key information is that this allergy is caused by an immune reaction to the carbohydrate galactose-alpha-1,3-galactose. The experimental treatment aims to prevent the addition of N-linked oligosaccharides during the synthesis of this carbohydrate. N-linked glycosylation is a process that occurs in the lumen of the endoplasmic reticulum and Golgi apparatus. Specifically, the addition of N-linked oligosaccharides occurs in the lumen of the rough endoplasmic reticulum. Therefore, the experimental drug likely targets the rough ER to prevent the N-linked glycosylation step in galactose-alpha-1,3-galactose synthesis.B: Rough endoplasmic reticulum 